Medicenna Therapeutics Past Earnings Performance
Past criteria checks 0/6
Medicenna Therapeutics's earnings have been declining at an average annual rate of -15.1%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-15.1%
Earnings growth rate
0.05%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -82.8% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Medicenna extends period to exercise certain warrants
Sep 30Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment
Sep 13Medicenna Therapeutics GAAP EPS of -$0.07 in-line
Aug 15Medicenna Therapeutics stock slides on launch of units offering
Aug 08Medicenna Therapeutics reports FY results
May 28Medicenna posts positive data from mid-stage brain cancer study
May 07Medicenna announces ATM sales facility for $25M
Dec 31Medicenna Therapeutics reports Q2 results
Nov 13Revenue & Expenses BreakdownBeta
How Medicenna Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -15 | 6 | 11 |
30 Sep 23 | 0 | -12 | 7 | 10 |
30 Jun 23 | 0 | -9 | 7 | 10 |
31 Mar 23 | 0 | -10 | 7 | 9 |
31 Dec 22 | 0 | -9 | 8 | 9 |
30 Sep 22 | 0 | -13 | 8 | 9 |
30 Jun 22 | 0 | -20 | 8 | 13 |
31 Mar 22 | 0 | -23 | 8 | 15 |
31 Dec 21 | 0 | -25 | 8 | 17 |
30 Sep 21 | 0 | -26 | 8 | 17 |
30 Jun 21 | 0 | -21 | 8 | 13 |
31 Mar 21 | 0 | -17 | 7 | 11 |
31 Dec 20 | 0 | -14 | 5 | 9 |
30 Sep 20 | 0 | -11 | 4 | 8 |
30 Jun 20 | 0 | -9 | 3 | 7 |
31 Mar 20 | 0 | -8 | 2 | 6 |
31 Dec 19 | 0 | -7 | 2 | 4 |
30 Sep 19 | 0 | -6 | 2 | 4 |
30 Jun 19 | 0 | -5 | 2 | 3 |
31 Mar 19 | 0 | -5 | 2 | 3 |
31 Dec 18 | 0 | -5 | 2 | 3 |
30 Sep 18 | 0 | -5 | 2 | 3 |
30 Jun 18 | 0 | -6 | 2 | 4 |
31 Mar 18 | 0 | -7 | 2 | 5 |
31 Dec 17 | 0 | -11 | 2 | 6 |
30 Sep 17 | 0 | -11 | 2 | 7 |
30 Jun 17 | 0 | -10 | 2 | 6 |
31 Mar 17 | 0 | -8 | 2 | 4 |
31 Dec 16 | 0 | -3 | 1 | 2 |
30 Sep 16 | 0 | -2 | 1 | 1 |
30 Jun 16 | 0 | -1 | 1 | 1 |
31 Mar 16 | 0 | -1 | 0 | 1 |
31 Mar 15 | 0 | -1 | 0 | 1 |
Quality Earnings: MDNA.F is currently unprofitable.
Growing Profit Margin: MDNA.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDNA.F is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.
Accelerating Growth: Unable to compare MDNA.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDNA.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MDNA.F has a negative Return on Equity (-82.76%), as it is currently unprofitable.